Retatrutide certificate of analysis, lot PL-2610-168
Certificate PL-26-00281 reports the release tests for Retatrutide lot PL-2610-168: 99.51% purity by reverse-phase HPLC and identity confirmed by LC-MS, tested October 7, 2026. The lot number printed on each unit matches this certificate.
| Certificate number | PL-26-00281 |
|---|---|
| Lot number | PL-2610-168 |
| Compound | Retatrutide 20 mg |
| Sequence | H-Y-Aib-QGTFTSDYSI-[αMeLeu]-LDKK(AEEA-γGlu-C20 diacid)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH₂ (39 residues; Aib2, α-methyl-Leu13, Aib20; Lys17 acylated with eicosanedioic acid via γ-Glu and AEEA; C-terminal amide) |
| Molecular formula | C221H342N46O68 |
| CAS number | 2381089-83-2 |
| Purity (RP-HPLC) | 99.51% |
| Identity (LC-MS) | Conforms (4,731.10 Da) · expected 4731.33 Da, found 4731.1 Da |
| Method | RP-HPLC (UV 214 nm) + LC-MS |
| Tested | October 7, 2026 |
| Retest by | October 6, 2028 |
| Tested by | Manufacturer’s in-house laboratory (not an independent third-party test) |
| Conclusion | Conforms |
Tests run on this lot
| Test | Method | Specification | Result |
|---|---|---|---|
| Identity (mass) | LC-MS, ESI positive | Theoretical ± 1.0 Da | 4,731.10 Da (PASS) |
| Purity | RP-HPLC, UV 214 nm, area% | ≥ 99.0% | 99.51% (PASS) |
| Largest impurity | RP-HPLC, area% | ≤ 1.0% | 0.27% (RT 19.60) (PASS) |
| Water content | Karl Fischer | ≤ 5.0% | 2.71% (PASS) |
| Bacterial endotoxin | LAL, kinetic | ≤ 5.0 EU/mg | 0.259 EU/mg (PASS) |
| Sterility | USP <71>, 14-day | No growth | No growth (PASS) |
What these results mean
HPLC purity is the share of UV-detectable material that elutes as the target compound; it is not the same as net peptide content, which also accounts for water and counter-ions. Identity means the measured mass matched the mass calculated for the compound. A certificate reports only the tests run on this lot; endotoxin, sterility and contaminant panels are not part of standard lot release. How to read a certificate of analysis.
Retatrutide · Verify this certificate · All certificates
Other Retatrutide lots
- PL-26-00285, lot PL-2610-172, 99.23%, tested October 7, 2026
- PL-26-00284, lot PL-2610-171, 99.37%, tested October 7, 2026
- PL-26-00283, lot PL-2610-170, 99.22%, tested October 7, 2026
- PL-26-00282, lot PL-2610-169, 99.50%, tested October 7, 2026
- PL-26-00280, lot PL-2610-167, 99.40%, tested October 7, 2026
- PL-26-00279, lot PL-2610-166, 99.29%, tested October 7, 2026
- PL-26-00087, lot PL-2609-087, 99.27%, tested September 19, 2026
- PL-26-00086, lot PL-2609-086, 99.35%, tested September 19, 2026
All products currently listed on this site are for research purposes only. Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.